Br[CH:2]1[CH2:14][CH2:13][C:5]2[N:6]=[C:7]([NH:9][C:10](=[O:12])[CH3:11])[S:8][C:4]=2[C:3]1=O.[CH3:16][C:17]([CH3:22])([CH3:21])[C:18]([NH2:20])=[S:19]>CO.[OH-].[O-2].[P-3].[Mo]>[C:17]([C:18]1[S:19][C:2]2[CH2:14][CH2:13][C:5]3[N:6]=[C:7]([NH:9][C:10](=[O:12])[CH3:11])[S:8][C:4]=3[C:3]=2[N:20]=1)([CH3:22])([CH3:21])[CH3:16]N-(6-Bromo-7-oxo-4,5,6,7-tetrahydro-benzothiazol-2-yl)-acetamide (Stage T.3, 473 mg, 1.635 mmol) was dissolved in MeOH (10 mL), 2,2-dimethylthio propionamide (230 mg, 1.962 mmol) and ammonium phosphomolybdate (307 mg, 0.164 mmol) were added, and the RM was stirred at 25° C. for 20 h. The RM was then stood for 2 days before stirring at 50° C. for 24 h. The mixture was extracted with EtOAc/H2O. The organic layers were dried over Na2SO4 and evaporated. The crude material was chromatographed with 30 g of silica gel, eluent DCM/MeOH=99:1. Fractions containing the product were evaporated and lyophilized from dioxane to give 225 mg of the title compound as a white solid (M+H=308; M−H=306; tR 5.525 min (Method F)).
Wird geladen…
